Natural Product (NP) Details

General Information of the NP (ID: NP6293)
Name
Myo-inositol
Synonyms
inositol; myo-inositol; Scyllo-inositol; Muco-Inositol; epi-Inositol; Allo-inositol; i-Inositol; meso-Inositol; 87-89-8; Neo-inositol; 1D-Chiro-inositol; 1L-Chiro-inositol; cis-Inositol; D-chiro-Inositol; Myoinositol; 643-12-9; 488-59-5; Scyllitol; D-(+)-chiro-Inositol; Cyclohexane-1,2,3,4,5,6-hexaol; 6917-35-7; mesoinositol; Meat sugar; cyclohexane-1,2,3,4,5,6-hexol; Myoinosite; Quercinitol; Dambose; 488-58-4; Cocositol; Inositene; Inositina; Phaseomannite; Inosital; Inosite; Iso-inositol; 551-72-4; L-chiro-Inositol; Cyclohexitol; Phaseomannitol; Mesoinosit; Mesoinosite; Scyllite; Mesovit; Nucite; Mesol; chiro-inositol; Cyclohexanehexol; Inositol, meso-; Inositol, myo-; Hexahydroxycyclohexane; L-Inositol; 41546-34-3; D-myo-Inositol; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; 643-10-7; Bios I; Insitolum; Isoinositol; (-)-Inositol; L-myo-Inositol; Inositol, i-; L-(-)-chiro-Inositol; Inositol (VAN); 488-55-1; Inositol, allo-; Inositol, muco-; 1D-myo-Inositol; 1L-myo-Inositol; 488-54-0; 1,2,3,4,5,6-Cyclohexanehexol; Rat antispectacled eye factor; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; MFCD00077932; Levoinositol; CCRIS 6745; AZD 103; Inositol, epi-; 576-63-6; Inositol, scyllo-; UNII-63GQX5QW03; UNII-8LQ63P85IC; UNII-9O6Y5O4P9W; UNII-R1Y9F3N15A; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; ELND005; 1,3,5/2,4,6-Hexahydroxycyclohexane; UNII-4661D3JP8D; UNII-6R79WV4R10; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1-L-chiro-Inositol; (-)-chiro-Inositol; UNII-1VS4X81277; CHEBI:17268; AI3-16111; NSC8101; 1,3,5/2,4,6-cyclohexanehexol; UNII-4L6452S749; UNII-587A93P465; 1,2,3,5/4,6-Cyclohexanehexol; NSC 8101; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; MFCD00065455; NSC404118; Inositol, myo- (8CI); myo-Inositol;meso-Inositol; 1,2,3,4,5,6-Hexahydroxycyclohexane; NSC 404118; 63GQX5QW03; 8LQ63P85IC; 9O6Y5O4P9W; R1Y9F3N15A; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; MI; CHEBI:10642; CHEBI:23927; CHEBI:27372; CHEBI:27987; 4661D3JP8D; 6R79WV4R10; Inositol (VAN8C; NSC-8101; NSC45517; NSC55551; NSC55552; NSC-25142; NSC-55551; UNII-M94176HJ2F; 1VS4X81277; NSC-404118; INS; Inositol, 98+%; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; NCGC00159409-02; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 4L6452S749; 587A93P465; DSSTox_CID_3146; D-chiro Inositol; DSSTox_RID_76890; DSSTox_GSID_23146; 1,3,4,5,6-Cyclohexanehexol; 1,3,5/4,6-Cyclohexanehexol; alloinositol; neoinositol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1,2,4/3,5,6-cyclohexanehexol; rel-(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexaol; rel-(1R,2r,3S,4R,5s,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; Mouse antialopecia factor; 1,2,3,4,5,6-Cyclohexanehexol #; cis-1,2,3,4,5,6-cyclohexanehexol; Inositol, cis-; Inositol, neo-; CAS-87-89-8; cis-1,3,5-trans-4,6-Cyclohexanehexol; SMR000857145; SMR000857319; SMR000857320; M94176HJ2F; (+)-Inositol; Inositol NF 12; SR-05000001655; Chiro-inositol, (-)-; EINECS 201-781-2; inositols; Matezodambose; an inositol; Inositol [Nonspecific isomer]; Muscle sugar; ELND 005; inositol myo-; D-muco-Inositol; Inositol FCC; 4irx; Inositol, chiro-; rac-chiro-inositol; Inosital (TN); Inositol (NF); CBU; EINECS 207-681-5; EINECS 207-682-0; EINECS 209-000-7; EINECS 211-393-5; EINECS 211-394-0; EINECS 230-024-9; NSC 25142; EPIINOSITOL; (+)-Epi-Inositol; (+)-Chiro-Inositol; Epi-inositol, 98%; allo-Inositol, 97%; Inositol [USAN:NF]; INOSITOL, MESO; Spectrum_001595; 2os9; myo-Inositol-C-[d6]; orthorhombic myo-inositol; D-(+)-Chiro Inositol; J101.890F; J101.891D; Chiro-inositol, (+)-; INOSITOL (D); INOSITOL (L); Spectrum3_001053; Spectrum4_001193; Spectrum5_000961; myo-Inositol, >=99%; bmse000102; bmse000103; bmse000113; bmse000901; bmse000922; Epitope ID:144993; scyllo-Inositol, >=98%; SCHEMBL5831; SCHEMBL5832; SCHEMBL5969; NCIOpen2_008191; BSPBio_002606; KBioGR_001885; KBioSS_002075; 38876-99-2; MLS001332377; MLS001332378; MLS001335965; MLS001335966; MLS001335967; MLS001335968; SCHEMBL187278; SCHEMBL187397; SCHEMBL187796; SCHEMBL188106; SCHEMBL188237; SCHEMBL491333; SCHEMBL959404; SCHEMBL959405; AZD103; CHEMBL278373; CHEMBL468154; ELND-005; GTPL4495; GTPL4645; GTPL4648; GTPL4649; MEGxp0_001817; SCHEMBL1055883; SCHEMBL4748543; SCHEMBL6378921; SCHEMBL6468882; SCHEMBL6791918; CHEMBL1222251; CHEMBL1231671; CHEMBL1950780; CHEMBL3976780; DTXSID7023146; SCHEMBL12371461; SCHEMBL12377889; SCHEMBL12411898; SCHEMBL12711208; SCHEMBL12735687; SCHEMBL13058696; SCHEMBL13114115; SCHEMBL13114116; SCHEMBL13114128; SCHEMBL13207905; SCHEMBL13580047; SCHEMBL14542470; SCHEMBL21388397; ACon1_002457; CHEBI:22357; CHEBI:23311; CHEBI:24848; CHEBI:25492; CHEBI:27374; D-(+)-chiro-Inositol, 95%; KBio2_002075; KBio2_004643; KBio2_007211; KBio3_001826; L-(-)-chiro-Inositol, 95%; AZD-103; DTXSID30110000; DTXSID50905091; DTXSID60903982; myo-Inositol, p.a., 98.0%; 1,2,3,4,5/6-cyclohexanehexol; 1,2,3,4/5,6-cyclohexanehexol; 1,2,3/4,5,6-cyclohexanehexol; 1,2,4,5/3,6-cyclohexanehexol; HMS2091N13; HMS2230N03; HMS2235H05; HMS2235M23; HMS3369B06; HMS3369F20; HMS3373E05; Pharmakon1600-01500352; 1,2,3,4,5,6-Cyclohexanehexaol; BCP25172; HY-B1411; HY-N3021; NSC25142; NSC55558; ZINC1530357; D-myo-Inositol, Cell Culture Grade; Tox21_111642; Tox21_302035; 6643AB; ANW-43204; CCG-36096; cis-Inositol, >=98.0% (TLC); KM0846; MFCD00003863; MFCD00272608; MFCD00799555; MFCD00799556; MFCD01321249; NSC 55552; NSC 55558; NSC-45517; NSC-55552; NSC-55558; NSC103959; NSC127230; NSC757076; s4530; STL453612; epi-Inositol, >=98.0% (HPLC); 1,2,3,4,5,6/0-cyclohexanetetrol; AKOS006240678; AKOS006332036; AKOS015895894; AKOS015912905; AKOS015912934; AKOS015960429; AKOS015960633; AKOS015994742; AKOS024318869; Tox21_111642_1; ZINC100018867; ZINC100019018; ZINC100024490; ZINC100032893; ZINC100035580; ZINC100037751; ZINC100055570; ZINC100073149; ZINC100513675; ZINC101185827; ZINC102201844; ZINC103574430; ZINC103574467; ZINC103574475; ZINC250615063; ZINC253837650; ZINC306121118; CS-4782; CS-W010757; DB03106; DB13178; DB15350; HY-W010041; KS-1284; KS-1420; MCULE-2727773046; NSC 103959; NSC 127230; NSC-103959; NSC-127230; NSC-757076; VC30505; D-chiro-Inositol, >=98.0% (HPLC); NCGC00159409-03; NCGC00159409-04; NCGC00169828-01; NCGC00178580-01; NCGC00178580-03; NCGC00255362-01; AC-11070; AK546883; AS-10616; AS-68396; AS-68424; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; K572; LS-13189; NCI60_041778; SY060836; myo-Inositol, purum, >=98.0% (HPLC); rac-chiro-1,2,3,4,5,6-cyclohexanehexol; SBI-0051369.P003; AB0014290; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; DB-051583; DB-051584; DB-054642; HY-121962; myo-Inositol, for microbiology, >=99.0%; CS-0023004; CS-0083766; FT-0627237; FT-0632208; FT-0632209; FT-0632730; FT-0652045; FT-0670351; FT-0670357; FT-0693444; FT-0693614; I0040; I0628; I0629; I0630; I0631; I0632; I0633; S6176; ST50406013; myo-Inositol, BioUltra, >=99.5% (HPLC); myo-Inositol, SAJ special grade, >=99.0%; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; 3635-EP2280282A1; 3635-EP2289886A1; 3635-EP2292088A1; 3635-EP2295417A1; 3635-EP2295437A1; 3635-EP2298312A1; 3635-EP2298775A1; 3635-EP2305636A1; 3635-EP2305677A1; 3635-EP2305682A1; 3635-EP2308879A1; C00137; C06151; C06152; C06153; C19891; D08079; I-6500; K-9876; M01914; 12513-EP2277880A1; 12513-EP2277881A1; 12513-EP2292597A1; 12513-EP2292610A1; 12513-EP2298744A2; 12513-EP2298768A1; 12513-EP2305825A1; 12513-EP2316831A1; 12513-EP2374790A1; 13719-EP2269977A2; 13719-EP2280010A2; 13719-EP2289891A2; 13719-EP2295437A1; 13719-EP2298734A2; 13719-EP2298775A1; 13719-EP2308875A1; 13719-EP2311831A1; 13719-EP2316836A1; 2-Cyano-N-(2,4,6-trimethyl-phenyl)-acetamide; 40032-EP2298312A1; 40032-EP2311830A1; AB00051982_13; 643C129; A834712; A836375; Q407997; Q743661; Q-201583; Q2838375; Q2974313; Q3011024; Q3023527; Q3205874; Q3331426; Q3347078; Q3589114; SR-05000001655-1; SR-05000001655-5; W-202861; W-202862; W-203081; W-203168; W-203392; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; D-MYO-INOSITOL-1,2,5,6-TETRAPHOSPHATE SODIUM SALT; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, United States Pharmacopeia (USP) Reference Standard; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; 2H3; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.
    Click to Show/Hide
Species Origin Fragaria x ananassa ...     Click to Show/Hide
Fragaria x ananassa
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Rosales
Family: Rosaceae
Genus: Fragaria
Species: Fragaria x ananassa
Disease Alzheimer disease [ICD-11: 8A20] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C6H12O6
PubChem CID
892
Canonical SMILES
C1(C(C(C(C(C1O)O)O)O)O)O
InChI
1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H
InChIKey
CDAISMWEOUEBRE-UHFFFAOYSA-N
CAS Number
CAS 551-72-4
ChEBI ID
CHEBI:17268
Herb ID
HBIN036059
SymMap ID
SMIT01697
TTD Drug ID
D03SHD
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine      Lung cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model The animal models were established in mice by a mixture of B[a]P plus NNK.
                    Experimental
                    Result(s)		 PEITC-NAC plus MI was significantly more effective than the agents alone.
Target and Pathway
Target(s) Amyloid beta A4 protein (APP)  Molecule Info  [1]
Mycobacterium Phosphatidylinositol synthase (MycB pssA)  Molecule Info  [3]
KEGG Pathway Notch signaling pathway Click to Show/Hide
2 Alzheimer's disease
Reactome Nuclear signaling by ERBB4 Click to Show/Hide
2 Degradation of the extracellular matrix
3 Regulated proteolysis of p75NTR
4 NRIF signals cell death from the nucleus
5 Activated NOTCH1 Transmits Signal to the Nucleus
6 Constitutive Signaling by NOTCH1 PEST Domain Mutants
7 Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
8 EPH-ephrin mediated repulsion of cells
WikiPathways Notch Signaling Pathway Click to Show/Hide
2 Signaling by ERBB4
3 Signaling by NOTCH3
4 Signaling by NOTCH4
5 Signaling by NOTCH1
6 Signaling by NOTCH2
7 Notch Signaling Pathway
8 Alzheimers Disease
9 Signalling by NGF
References
Reference 1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Reference 2 Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 2002 Sep;23(9):1455-61.
Reference 3 Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50.
 Download Picture         KEGG Link